Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023

Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

Altimmune is a pioneer in creating peptide-based therapies for obesity and liver disease, with a unique approach to product development. Altimmune's R&D expenses have dropped year-on-year due to the discontinuation of certain projects, but the company has been actively advancing other programs that are expected to deliver noteworthy revenues soon.

Altimmune's Peptide-Based Therapies Offer Substantial Opportunity

Altimmune has exposure to promising growth areas of obesity and non-alcoholic liver disease treatment. Upcoming trial data and proof of concept work for its pemvidutide compound is key to see the stock rate higher.

Altimmune: Potential Dual Action For Pemvidutide In Obesity, NASH

GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.

Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

Foghorn Therapeutics

Precigen

Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week

iShares Russell 2000 ETF

Marathon Digital Holdings

Proterra

Schwab U.S. Small-Cap ETF

Taseko Mines

Some of the greatest opportunities can be found in these small-cap stocks to buy. For one, a good number of small-cap stocks are severely undervalued.

7 Small-Cap Stocks with Big Growth Potential in 2023

Mr. Jordt brings over 25 years of industry experience in corporate strategy and business development Mr. Jordt brings over 25 years of industry experience in corporate strategy and business development

Altimmune Appoints Raymond Jordt as Chief Business Officer

GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune's recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Details for the oral presentation are as follows:

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

Altimmune Inc (NASDAQ:ALT) and SINTX Technologies Inc (NASDAQ:SINT) are trending today.

Altimmune Stock Skyrockets on NAFLD Drug Trial Data

GAITHERSBURG, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD.

Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)

AbbVie

Ardelyx

Axsome Therapeutics

ProShares Ultra Nasdaq Biotechnology

Krystal Biotech

SPDR S&P Biotech ETF

Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond

On September 14, shares plummeted 27% on topline results from a Phase 1 study of pemvidutide. Reductions in liver fat appear to be substantially better than that of the two leading drug candidates for nonalcoholic steatohepatitis.

Altimmune Appears To Have A Winner, But Will The Market Believe?

Karuna Therapeutics Inc

Viking Therapeutics

My 3 Top Biotech Stock Picks for 2023

Altimmune, Inc. (NASDAQ:ALT ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Richard Eisenstadt - CFO Vipin Garg - President & CEO Scot Roberts - Chief Scientific Officer Scott Harris - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore ISI Mayank Mamtani - B. Riley Jon Wolleben - JMP Securities Operator Good day, ladies and gentlemen, and welcome to the Altimmune, Inc. Third Quarter Financial Results Conference Call.

Altimmune, Inc. (ALT) Q3 2022 Earnings Call Transcript

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates

Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022

Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update.

Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10

GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022:

Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®

Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023 Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023

Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

Altimmune stock was trading lower after the release of positive results, achieving both primary and secondary endpoints of phase 1b study with pemvidutide in NASH/obese patients provides a buying opportunity. It provided updated 24-week results from phase 1b study using pemvidutide in NASH/obese patients measuring weight loss expected Q4 of 2022.

Altimmune: Overreaction On NASH Data Creates Buying Opportunity

Source: Shutterstock Altimune (NASDAQ: ALT ) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning. That clinical trial concerns the use of pemvidutide1 in treating patients with NAFLD.

Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data

Shares of Altimmune Inc. ALT, -0.39% tumbled 44.4% in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcoholic fatty liver disease that failed to impress investors. The Phase 1b study met both the primary and secondary endpoints of reduction in liver fat content and weight loss, respectively.

Altimmune's stock falls 44% after sharing data from trial for liver disease treatment

GAITHERSBURG, Md., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive topline results from its 12-week Phase 1b study of pemvidutide1 in subjects with non-alcoholic fatty liver disease (NAFLD).

Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

Altimmune, Inc. (NASDAQ:ALT ) Q2 2022 Results Conference Call August 11, 2022 8:30 AM ET Company Participants Richard Eisenstadt - Chief Financial Officer Vipin Garg - President and Chief Executive Officer Scot Roberts - Chief Scientific Officer Scott Harris - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Yasmeen Rahimi - Piper Sandler Roger Song - Jefferies Mayank Mamtani - B. Riley Jon Welandon - JMP Securities Patrick Trucchio - H.C.

News for Altimmune Stock (ALT)